🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for HER2 Gene Mutation

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites📍 Freiburg im Breisgau📍 Paderborn📍 Ravensburg iOMEDICO AG · Tests: Elacestrant, Standard of care (Investigator Choice) Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187Phase 213 sites📍 Atlanta📍 Chicago📍 Boston Dana-Farber Cancer Institute · Tests: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites📍 Bordeaux📍 Caen📍 Clermont-Ferrand Institut Claudius Regaud · Tests: Main study:, Sub-study: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cediranib, Ceralasertib, Olaparib Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470Phase 21 site📍 Guangzhou Ying Lin · Tests: Camrelizumab, Fluzoparib, Nab-paclitaxel A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562Phase 115 sites📍 Scottsdale📍 Scottsdale📍 New Haven Cogent Biosciences, Inc. · Tests: CGT4255 Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: Disitamab Vedotin + tislelizumab + bevacizumab Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites📍 Aviano📍 Brescia📍 Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: Palbociclib, Ribociclib, Abemaciclib A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites📍 Scottsdale📍 Los Angeles📍 Palo Alto Cogent Biosciences, Inc. · Tests: CGT6297 A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer NCT06123338Phase 210 sites📍 Boston📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine, 5-Fluorouracil Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521Phase 3243 sites📍 Gilbert📍 Beverly Hills📍 Duarte Relay Therapeutics, Inc. · Tests: Zovegalisib, Capivasertib, Fulvestrant A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer NCT07405801Phase 258 sites📍 Anaheim📍 Palo Alto📍 Jacksonville Hoffmann-La Roche · Tests: Inavolisib, Ribociclib, Fulvestrant, Placebo First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172Phase 1, Phase 294 sites📍 Gilbert📍 Duarte📍 Atlanta Bayer · Tests: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3 Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer NCT06548919n/a1 site📍 Suzhou SciClone Pharmaceuticals · Tests: Endocrine therapy, Chemotherapy Prednisone Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC NCT05681780Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer NCT06201234Phase 236 sites📍 Stuttgart📍 Tübingen📍 Winnenden GBG Forschungs GmbH · Tests: Olaparib + Elacestrant, Olaparib First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations NCT06043817Phase 1, Phase 225 sites📍 Duarte📍 Huntington Beach📍 Irvine Pierre Fabre Medicament · Tests: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels), STX-721/PFL-721 (RP2D) HEAT Trial (HER2 Antibody Therapy With Lutetium-177) NCT06824155EARLY Phase 15 sites📍 Kingswood📍 Macquarie Park📍 Wollongong Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD202 First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors NCT05768139Phase 1, Phase 265 sites📍 Los Angeles📍 San Francisco📍 Aurora Eli Lilly and Company · Tests: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metastatic Breast Cancer (mBC) Patients, NCT06762483n/a1 site📍 Milan European Institute of Oncology Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer NCT06488378Phase 12 sites📍 Boston📍 Rochester Dana-Farber Cancer Institute · Tests: Axatilimab, Olaparib A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations NCT06706076Phase 1, Phase 242 sites📍 Phoenix📍 Irvine📍 La Jolla BlossomHill Therapeutics · Tests: BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study NCT05576389Phase 21 site📍 Beijing Peking University People's Hospital · Tests: Camrelizumab+Fluzoparib A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06760819Phase 254 sites📍 Birmingham📍 Duarte📍 Fort Myers Bayer · Tests: BAY2927088 A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery NCT06127979NA1 site📍 New York Memorial Sloan Kettering Cancer Center · Tests: blood draw A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer NCT07766018Phase 219 sites📍 Chiba📍 Fukuoka📍 Fukuoka Stemline Therapeutics, Inc. · Tests: Elacestrant Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. NCT06382948Phase 3104 sites📍 Innsbruck📍 Linz📍 Schwaz MedSIR · Tests: Everolimus, Elacestrant, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizin… A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) NCT07174336Phase 3363 sites📍 Anchorage📍 Chandler📍 Phoenix Eli Lilly and Company · Tests: LY4064809, Placebo, Ribociclib, Palbociclib, Abemaciclib
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy